Ytracis
yttrium [90Y] chloride
Table of contents
Overview
The marketing authorisation for Ytracis has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Ytracis
|
| Agency product number |
EMEA/H/C/000460
|
| Active substance |
yttrium (90Y) chloride
|
| International non-proprietary name (INN) or common name |
yttrium [90Y] chloride
|
| Therapeutic area (MeSH) |
Radionuclide Imaging
|
| Anatomical therapeutic chemical (ATC) code |
V09
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
CIS bio international
|
| Revision |
7
|
| Date of issue of marketing authorisation valid throughout the European Union |
24/03/2003
|
| Contact address |
Route Nationale 306, Saclay |
Product information
29/05/2015 Ytracis - EMEA/H/C/000460 - IAIN/0016
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Diagnostic radiopharmaceuticals
Therapeutic indication
To be used only for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.
Radiopharmaceutical precursor - Not intended for direct application to patients.